Appendices to published papers

Contact Information





The CHRU conducts epidemiologic and health-services research addressing cardiovascular disease risk factors and outcomes in adults. Funding of our research is primarily from public sources such as the National Heart, Lung, and Blood Institute (NHLBI) and National Institute on Aging (NIA) within the National Institutes of Health. We are also recipients of funds from non-profit organizations and foundations such as the American Heart Association (AHA). Below is a list of current projects that are part of the CHRU portfolio. Listed are project titles, principal investigators, and a brief description of the scope of the work.



Androgens & Subclinical Atherosclerosis in Young Adults

David S. Siscovick, MD, MPH, Principal Investigator

This is an ancillary study to the CARDIA study (see below) funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). This study proposes to examine whether serum androgen levels and variations in genes related to androgen use in the body are associated with early-onset of subclinical coronary artery disease. The study will also look at whether changes in obesity, physical inactivity, and insulin levels influence the association between elevated androgens and genetic variants and early heart disease.


Anti-hypertensive Drug-Gene Interactions and Cardiovascular Events

Bruce M. Psaty, MD, PhD, Principal Investigator

The primary aims of this NHLBI-funded study are to assess drug-gene interactions on the incidence of myocardial infarction and stroke. The study will look at certain gene interactions with diuretics, beta-blockers, and ACE inhibitors, all commonly used medications to treat hypertension. The setting is Group Health.


Atrial Fibrillation Incidence, Risk Factors and Genetics

Susan R. Heckbert, MD, PhD, Principal Investigator

This NHLBI-funded Project seeks to assess the safety of commonly used medications in relation to the risk of atrial fibrillation (AF, irregular heart beats).  It will also look at the association of several genetic mutations with stroke risk after AF onset. The setting is Group Health.


Polyunsaturated Fats and Risk of Primary Cardiac Arrest (CABS)

David S. Siscovick, MD, MPH, Principal Investigator

The CABS study, funded by NHLBI, is a community-based case-control study that explores the relation of dietary long-chain omega-3 polyunsaturated fatty acids (PUFA) intake, red-cell membrane omega-3 PUFA levels, and the risk of primary cardiac arrest.


Cardiovascular Research and Training Activities

David S. Siscovick, MD, MPH, Principal Investigator

This project is designed to develop a set of related research and training activities that will bridge the research and training strengths of the University of Washington Cardiovascular Health Research Unit with the strengths of the newly-funded Donald W. Reynolds Foundation Clinical Cardiovascular Research Center at the University of Texas Southwestern Medical Center in Dallas, Texas.


Coronary Artery Risk Development in Young Adults (CARDIA)

David S. Siscovick, MD, MPH, Principal Investigator

This multi-site study was initiated in 1984 by NHLBI to provide a better understanding of the trends and determinants of coronary heart disease in the US.  This longitudinal study focuses on young adults, who were between 18 and 30 years of age at the time study entry.


Hormone Replacement Therapy, Procoagulant Variants, and Risk of Myocardial Infarction and Stroke

Bruce M. Psaty, MD, PhD, Principal Investigator

The purpose of this NHLBI-funded study is to examine the potential interaction of hormone replacement therapy with other genetic mutations on the risk of cardiovascular events, both heart attack and stroke. The setting is Group Health.


Project title: Inflammation Genomics and Atherosclerosis

David S. Siscovick, MD, MPH, Principal Investigator

This NHLBI-funded ancillary study to the CARDIA study will look at the role certain variations in inflammation/thrombosis genes play in the development of subclinical coronary atherosclerosis in young adults. This study will also explore possible gene-gene and gene-environment interactions.


Inflammation/Thrombosis Genomics and Acute MI

David S. Siscovick, MD, MPH, Principal Investigator

The objective of this proposal, funded by the Doris Duke Charitable Foundation, is to demonstrate the effectiveness of a novel approach to look at the biology of inflammation and thrombosis pathways, human genomics (science of the genome), and clinical epidemiology to determine the role that genes play in the development of cardiovascular disease.


Trends in the Use of Cardiovascular Medications in Older Adults

Bruce M. Psaty, MD, PhD, Principal Investigator

This is an ancillary study to the Cardiovascular Health Study (CHS), a longitudinal study of over 6000 older adults funded by the National Institute on Aging (NIA). The purpose of this study is to assess the efficacy and safety of a variety of cardiovascular and non-cardiovascular medications in the elderly.


Clotting Genetic Variants, Hormones, & Venous Thrombosis

Nicholas L. Smith, PhD, Principal Investigator

The primary aim of this NHLBI-funded project is to assess the interaction between hormone therapy, either replacement therapy in post-menopausal women or contraceptive therapy in younger women, and genetic variation in the major clotting factors and the risk of incident venous thrombosis in women 18-89 years of age. The setting for this population-based case-control study is at Group Health.



General Internal Medicine | Department of Medicine | Department of Epidemiology | University of Washington

Please honor our copyrights and disclaimer.
1998 University of Washington. All rights reserved.
Comments to CHRU,
Last reviewed: February 02, 2007 - Last updated: February 02, 2007